Allogene Therapeutics ALLO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's additional paid-in capital?
- Allogene Therapeutics (ALLO) reported additional paid-in capital of $2.33B in Q1 2026.
- How has Allogene Therapeutics's additional paid-in capital changed year-over-year?
- Allogene Therapeutics's additional paid-in capital increased by 3.0% year-over-year, from $2.26B to $2.33B.
- What is the long-term trend for Allogene Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Allogene Therapeutics's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $1.73B to $2.3B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.